What are the side effects of minoxidil, and can oral minoxidil affect your heart?

Short version: yes, minoxidil can have side effects, some of them can involve the heart, and nobody should decide on their own whether the drug is right for them. Talk to a doctor before you start minoxidil in any form, tell them about any heart, blood-pressure, kidney or liver condition and every medicine you take, and if you develop chest pain, a racing or irregular heartbeat, shortness of breath, fainting, swelling or sudden weight gain while using it, stop and seek medical care.

Minoxidil comes in two forms. The topical liquid or foam is sold over the counter for hair loss. The tablet is a blood-pressure medicine that some dermatologists prescribe off-label for hair loss at a small fraction of its blood-pressure dose, usually called low-dose oral minoxidil (LDOM). Because the drug works by widening blood vessels and lowering blood pressure, most questions about its safety are really questions about the heart and circulation. What follows is a summary of what published studies and product labels say. It is not medical advice, and the numbers below come from studies with real limitations.

Topical minoxidil: what the label and studies report

The most common problems with the topical product are local. Studies and product labelling describe scalp itching, dryness, flaking and contact dermatitis; the irritation is commonly attributed to propylene glycol in liquid solutions, which is why foam formulations were developed without it. Many users describe a temporary increase in shedding in the first weeks, and unwanted hair on the face or neck can occur where the product spreads.

Systemic effects from the topical form are considered uncommon because little of the drug is absorbed through the scalp, but they are not impossible, and absorption can be higher on damaged or inflamed skin or when more than the labelled amount is used. The US over-the-counter Drug Facts label instructs users to stop use and ask a doctor if chest pain, rapid heartbeat, faintness or dizziness occurs, if sudden unexplained weight gain occurs, or if the hands or feet swell. It also states the product may be harmful if used when pregnant or breast-feeding. Those instructions are the manufacturer's own standard for the topical product, and they are a sensible standard for the oral form too.

Oral minoxidil: what the studies found, and what they could not

The largest safety dataset is a retrospective multicenter study of 1,404 patients treated with low-dose oral minoxidil for at least three months (Vañó-Galván et al., 2021). The most frequent adverse effect was hypertrichosis, extra hair on the body or face, in 15.1% of patients. Systemic effects were less common in that cohort: lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), swelling around the eyes (0.3%) and insomnia (0.2%). Systemic effects led 1.2% of patients to stop the drug, and the authors observed no life-threatening events. The authors list the retrospective design and the lack of a control group as limitations, which means the study can describe what happened to these patients but cannot prove how often the drug causes these problems in general.

A systematic review and meta-analysis of blood-pressure data reported that low-dose oral minoxidil did not significantly change systolic or diastolic blood pressure on average (mean arterial pressure showed a borderline, non-significant fall of about 1.9 mmHg, which the authors called a strong tendency), but did produce a small, statistically significant rise in heart rate, about 2.7 beats per minute (Chen et al., 2024). Symptoms suggestive of low blood pressure were reported by 5.0% of patients. Again, the included studies lacked control groups and varied in how they monitored blood pressure, so an average result across studies does not tell an individual what will happen to them.

A 2025 narrative review of the adverse-event literature puts fluid retention at 1.3–10% of patients, more often in women and usually in the first one to three months, and tachycardia or dizziness in fewer than 5%, usually described as mild and transient. It describes severe events such as pericardial effusion as extremely rare and often linked to compounding errors that delivered an excessive dose (Jimenez-Cauhe et al., 2025). A 2026 review reports higher hypertrichosis figures (about 24%), transient shedding in 16–22% and mild peripheral edema in about 2%, and lists pericardial disease, uncontrolled hypertension and pregnancy as contraindications (Ong et al., 2026).

Two cautions apply to all of these figures. Oral minoxidil for hair loss is off-label, so there is no regulator-approved dose or safety label for this use, and most of the evidence is observational and relatively recent. Rare events are exactly what such studies are least able to detect.

The heart question: pericarditis and fluid around the heart

The US prescribing label for minoxidil tablets carries a boxed warning: the drug can cause pericardial effusion (fluid collecting in the sac around the heart), occasionally progressing to tamponade, and it can worsen angina. For high blood pressure, the label says it must be given under close supervision, usually with a beta-blocker and a diuretic. The label reports pericardial effusion, occasionally with tamponade, in about 3% of treated patients not on dialysis, especially those with reduced kidney function (DailyMed, minoxidil tablets). These figures come from the high doses used for blood pressure (10–40 mg a day); controlled data at hair-loss doses do not exist. Lupus has also been described as a risk factor (Bentivegna et al., 2022; Zaminski et al., 2025). The question for hair-loss patients is whether the same thing can happen at hair-loss doses.

Case reports say it can. Dlova et al. (2022) described a previously healthy 40-year-old woman who developed pericardial and pleural effusions and generalized swelling after three weeks of low-dose oral minoxidil for frontal fibrosing alopecia. A reply letter reported pericarditis and peripheral edema in an otherwise healthy man on the drug (Bentivegna et al., 2022). In 2026, a JAAD Case Reports paper described pericarditis as an "unanticipated risk" of low-dose oral minoxidil (Zappi et al., 2026). These are individual cases, and the reviews above regard them as rare, but they happened in people without known heart disease, and case reports only capture events that a clinician recognised and chose to publish. A 2026 systematic review of 20 studies published since 2021 concluded that reports and pharmacovigilance signals involving fluid retention or pericardial effusion "require clinical vigilance but do not establish a causal excess risk", while noting that the evidence in people with hypertension or arrhythmias is limited by short follow-up and retrospective designs.

A newer and unsettled signal concerns the arteries rather than the heart itself. A small randomized study of 44 healthy young men, published as a preprint in 2026 and not yet peer reviewed, reported that oral minoxidil at 5 mg a day increased carotid intima-media thickness, a marker of artery-wall ageing, over the study period, with a dose-dependent pattern and no such change at 1 mg. Only 31 participants completed the study. It is a single small preprint and needs replication, but it is a reminder that the long-term cardiovascular effects of taking a vasodilator for years for a cosmetic condition have not been fully studied.

Who should be especially careful

Published reviews list pericardial disease, uncontrolled high blood pressure and pregnancy as reasons not to take oral minoxidil, and advise caution in people with kidney or liver impairment, in adolescents, and in anyone already taking blood-pressure medicines or other drugs that affect heart rate or fluid balance. People with a history of heart disease, heart rhythm problems, lupus or unexplained swelling should raise that history with the prescriber before anything else. This list is not exhaustive; a doctor who knows your history is the only person who can judge your individual risk.

Warning signs: stop and seek care

The case reports and the topical label point to the same warning signs. If any of the following appear while you are using minoxidil in either form, the standard on the label is to stop use and ask a doctor, and for severe or sudden symptoms to seek urgent care:

• chest pain, pressure or tightness, or pain that is worse when lying down or breathing in
• a fast, pounding or irregular heartbeat
• shortness of breath, or breathlessness when lying flat
• faintness, dizziness or fainting
• swelling of the ankles, legs, hands, face or around the eyes
• sudden, unexplained weight gain over a few days

Do not wait for a routine follow-up appointment if these symptoms are severe or getting worse.

Talk to a doctor before, during and after

Oral minoxidil is a prescription medicine, and its use for hair loss is off-label. Talk to a doctor or pharmacist before starting, stopping or combining it with anything else, including the topical form, blood-pressure medicines, and supplements. Do not change the dose on your own, do not use compounded or imported tablets of uncertain strength, and use a licensed pharmacy; several of the serious cases in the literature involved compounding or dosing errors. Ask your prescriber what monitoring they want, such as checking blood pressure and heart rate, and tell them about any new symptom, even one that seems minor. The same applies to the over-the-counter product: it is a drug, its label carries a stop-and-ask-a-doctor warning for a reason, and a doctor should know you are using it.

References

• Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021. PMID 33639244.
• Chen M, Weichert M, Guo W, Ruzic R, Briley J. Low-dose oral minoxidil does not significantly affect blood pressure: a systematic review and meta-analysis. J Am Acad Dermatol. 2024. PMID 39521141.
• Jimenez-Cauhe J, Lo Sicco KI, Shapiro J, et al. Characterization and management of adverse events of low-dose oral minoxidil treatment for alopecia: a narrative review. J Clin Med. 2025. PMID 40142611.
• Ong MM, Li Y, Lipner SR. Oral minoxidil for alopecia treatment: risks, benefits, and recommendations. Am J Clin Dermatol. 2026. PMID 41118052.
• Dlova NC, Jacobs T, Singh S. Pericardial, pleural effusion and anasarca: a rare complication of low-dose oral minoxidil for hair loss. JAAD Case Rep. 2022. PMID 36117778.
• Bentivegna K, Zhou AE, Adalsteinsson JA, Sloan B. Letter in reply: pericarditis and peripheral edema in a healthy man on low-dose oral minoxidil therapy. JAAD Case Rep. 2022. PMID 36267649.
• Zappi I, Spindler A, Maas D, et al. Pain in the heart, hair on the head: pericarditis as an unanticipated risk of low-dose oral minoxidil. JAAD Case Rep. 2026. PMID 42701670.
• Zaminski D, Alhanshali L, et al. Tolerability of low-dose oral minoxidil in patients with systemic lupus erythematosus: a retrospective cohort study. Int J Dermatol. 2025. PMID 40116155.
• Cardiovascular safety of low-dose oral minoxidil for androgenetic alopecia in patients with hypertension or arrhythmias (systematic review, 20 studies). Lumen et Virtus. 2026. https://doi.org/10.56238/levv17n63-024
• Dose-dependent increases in carotid intima-media thickness associated with oral minoxidil but not dutasteride in healthy young men (preprint, not peer reviewed). Preprints.org. 2026. https://doi.org/10.20944/preprints202606.1934.v1
• Minoxidil Tablets, USP prescribing information, boxed WARNINGS and "Pericarditis, Pericardial Effusion and Tamponade" section, DailyMed (American Health Packaging, setid 0b4fc036-9497-442b-b629-c4b386932789). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b4fc036-9497-442b-b629-c4b386932789
• Minoxidil 5% topical aerosol (foam) Drug Facts label, DailyMed, "Stop use and ask a doctor if" section (Kirkland Signature, setid 90137bb7-f0e3-4c3c-9cfb-d4d5eed13a9c).